CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop a new class of drugs that target the endocannabinoid system to treat post-traumatic stress disorder (PTSD). By restoring balance to brain chemistry, these drugs could provide effective relief for millions suffering from PTSD, a condition that currently lacks adequate treatment options.
PTSD affects over 15 million people in Europe.
So far, 70% never find relief.
New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders.
As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, night…
SYNENDOS THERAPEUTICS AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
